The Cooper Companies, Inc. (NASDAQ:COO) Shares Acquired by Centiva Capital LP

Centiva Capital LP increased its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 22.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,861 shares of the medical device company’s stock after purchasing an additional 1,066 shares during the period. Centiva Capital LP’s holdings in Cooper Companies were worth $539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in Cooper Companies by 517.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company’s stock worth $324,466,000 after purchasing an additional 2,957,421 shares during the period. Norges Bank acquired a new position in Cooper Companies during the fourth quarter worth $217,906,000. FMR LLC lifted its holdings in Cooper Companies by 97.6% during the fourth quarter. FMR LLC now owns 2,218,112 shares of the medical device company’s stock valued at $203,911,000 after purchasing an additional 1,095,805 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Cooper Companies during the fourth quarter worth about $64,826,000. Finally, Victory Capital Management Inc. lifted its stake in Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock valued at $415,985,000 after buying an additional 574,899 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Price Performance

Shares of COO opened at $82.27 on Friday. The firm has a 50-day simple moving average of $80.54 and a two-hundred day simple moving average of $91.03. The stock has a market cap of $16.45 billion, a PE ratio of 42.19, a P/E/G ratio of 2.25 and a beta of 1.08. The Cooper Companies, Inc. has a 1-year low of $69.81 and a 1-year high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. As a group, analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on COO shares. Piper Sandler reaffirmed an “overweight” rating and issued a $115.00 price target (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. BNP Paribas upgraded shares of Cooper Companies to a “hold” rating in a research report on Thursday, March 13th. JPMorgan Chase & Co. lowered their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Robert W. Baird cut their price objective on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.